[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"x-linked-retinitis-pigmentosa-xlrp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:x-linked-retinitis-pigmentosa-xlrp":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100591591","insightrp2-registry-100591591",false,"NCT06982417","InsightRP2 Registry","InsightRP2: a Global Patient Registry for RP2-associated Retinitis Pigmentosa","Inclusion Criteria:\n\n* A molecular genetic diagnosis involving a heterozygous or hemizygous variant in RP2 and a written informed consent to participate are required for access to the registry questionnaire. Patients of all ages meeting the above criteria will be allowed to participate. As documentation will be in English and German, those who can navigate these pages will be included.\n\nExclusion Criteria:\n\n* Patients with evidence of non-RP2 molecular genetic diagnoses will be excluded. Collection of data and further analysis will not be possible without the consent of the patient or legal guardian. Patients who cannot navigate registry documentation in English or German will be excluded.","ALL",{"count":18,"type":19},200,"ESTIMATED","OBSERVATIONAL","InsightRP2 is a secure online patient registry specific to RP2-associated retinitis pigmentosa (RP). It is our goal to further the scientific understanding of this rare disease and to support research in to a gene therapy for RP2-associated RP.\n\nWe collect medical, genetic and imaging data from people affected by RP2-associated RP and will coduct a natural history study as well as image analysis studies.",[23,24,25],"RP2-associated Retinitis Pigmentosa","X-Linked Retinitis Pigmentosa (XLRP)","Retinitis Pigmentosa 2",[27],"RP2, Retinitis pigmentosa, RP2-associated Retinitis pigmentosa","RECRUITING","2025-05-13",{"date":31,"type":32},"2025-05-21","ACTUAL",{"date":34,"type":32},"2025-05-01",{"date":36,"type":19},"2045-05-01",{"name":38,"class":39},"University of Göttingen","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":40},"100553958","phase-1-gene-therapy-for-rpgr-gene-mutation-associated-x-linked-retinitis-pigmentosa-100553958","NCT06492850","Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa","A Phase I\u002FII Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of FT-002 Subretinal Injection in Subjects With RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa.","Inclusion Criteria:\n\n* Subjects that are willing and able to follow study procedures including scheduled visits, treatment plan, and laboratory tests, and sign a written informed consent form;\n* Age: Phase I dose escalation stage, 18-45 years old male (including boundary value) at the time of signing the ICF; Phase II dose extension stage, males 8-45 years old (including boundary values) at the time of signing the ICF;\n* Clinically diagnosed XLRP, the main symptoms include but are not limited to night blindness, visual field loss, vision loss, etc.;\n\nExclusion Criteria:\n\n* Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.","MALE","8 Years","45 Years",{"count":52,"type":19},32,"INTERVENTIONAL",[55,56],"PHASE1","PHASE2","The aim of this study was to evaluate the safety, tolerability, and efficacy of one-time subretinal injection of FT-002 in male subjects (8-45 years of age) with RPGR (Retinitis Pigmentosa GTPase Regulator) gene mutation-associated X-linked retinitis pigmentosa, of XLRP. This study includes Phase I (dose escalation phase) and Phase II (dose expansion phase).",[24],[24,60],"FT-002","2024-07-01",{"date":63,"type":32},"2024-07-09",{"date":65,"type":32},"2024-04-01",{"date":67,"type":19},"2026-02-01",{"name":69,"class":70},"Frontera Therapeutics","INDUSTRY"]